SciTransfer
Organization

BEONCHIP SL

Spanish SME manufacturing microfluidic organ-on-chip and lab-on-chip devices for biomedical research and personalized medicine.

Technology SMEhealthESSMENo active H2020 projects
H2020 projects
4
As coordinator
1
Total EC funding
€481K
Unique partners
73
What they do

Their core work

BeOnChip is a Spanish SME based in Zaragoza that designs and manufactures microfluidic devices for biomedical research, specifically organ-on-chip and lab-on-chip platforms. Their core product line enables researchers to simulate human organ environments on compact chip systems, replacing or reducing animal testing in drug development and personalized medicine. They bridge microfabrication engineering with life sciences, providing ready-to-use microreactor hardware that academic labs and medical device companies integrate into their experimental workflows.

Core expertise

What they specialise in

Organ-on-chip and body-on-chip devicesprimary
3 projects

Core focus across B-On-Chip (their own coordinated project), CISTEM (heart-on-chip), and Moore4Medical (microfabricated medical devices).

Advanced printing for microdevicesemerging
1 project

PRIME project explores 4D printing, inkjet printing, and photo-responsive materials for next-generation active microfluidic devices.

1 project

Moore4Medical focused on accelerating innovation in microfabricated medical devices, their largest funded project at EUR 105,094.

Evolution & trajectory

How they've shifted over time

Early focus
Organ-on-chip for biomedicine
Recent focus
Advanced microdevice manufacturing

BeOnChip started with a tight focus on biological simulation — organ-on-chip platforms for personalized medicine, using iPSCs and cell differentiation techniques (B-On-Chip 2017, CISTEM 2018). From 2019 onward, they expanded into the manufacturing side of microfluidics, engaging with additive manufacturing, 4D printing, nanosensors, and photo-responsive materials through PRIME and Moore4Medical. This signals a shift from being purely a biomedical chip user to becoming a more versatile microdevice manufacturer with broader applications.

BeOnChip is evolving from a niche organ-on-chip provider toward a broader microfluidic platform company incorporating smart materials and advanced fabrication techniques.

Collaboration profile

How they like to work

Role: specialist_contributorReach: European17 countries collaborated

BeOnChip primarily joins consortia as a specialist partner (3 of 4 projects), contributing their microfluidic hardware expertise to larger research teams. They coordinated one early-stage SME Instrument project (B-On-Chip), demonstrating entrepreneurial initiative but preferring the contributor role in larger efforts. With 73 unique partners across 17 countries, they integrate easily into diverse European consortia — a practical, low-friction partner for teams needing microfluidic device capability.

Despite being a small company, BeOnChip has built a surprisingly wide network of 73 consortium partners spread across 17 countries, reflecting the interdisciplinary nature of organ-on-chip research that pulls in biologists, clinicians, engineers, and manufacturers from across Europe.

Why partner with them

What sets them apart

BeOnChip sits at the intersection of microfabrication and biomedical research — they are not just researchers studying organ-on-chip concepts, but an SME that builds and sells the actual hardware. This makes them a rare find for consortia that need a commercial microfluidic device partner rather than another academic lab. Their Zaragoza base connects them to Spain's growing biotech and advanced manufacturing ecosystem in Aragon.

Notable projects

Highlights from their portfolio

  • PRIME
    Largest funding (EUR 290,000) and represents their strategic pivot into advanced manufacturing with 4D printing and smart materials for microfluidic devices.
  • B-On-Chip
    Their only coordinated project — an SME Instrument Phase 1 for their flagship body-on-chip product, signaling commercial ambition beyond research participation.
  • Moore4Medical
    Positions them in the medical device commercialization pipeline, bridging research-grade microfluidics with regulated medical products.
Cross-sector capabilities
digital (sensor integration, lab-on-chip platforms)manufacturing (microfabrication, additive manufacturing, 4D printing)environment (potential for microfluidic sensing and water quality monitoring)
Analysis note: Profile based on 4 H2020 projects — enough to identify clear expertise in microfluidics and organ-on-chip, but limited volume means the evolution trend (toward advanced manufacturing) rests on just 1-2 later projects. Commercial product status and current activity beyond H2020 cannot be confirmed from this data alone.